{
  "id": 876290,
  "title": "STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more",
  "url": "https://urgent.news/2026/08/14/stat-pharmalittle-were-reading-about-a-lawsuit-over-lab-tests-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T14:00:17.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration has approved an oral treatment for advanced multiple myeloma, developed by Bristol Myers Squibb. This marks the first drug of its kind in a new class of medicines, called CELMoDs, which work by targeting cancer-causing proteins. The drug, sold under the brand name Zenbexus, represents a significant advancement in the treatment of blood cancer.",
  "summary": "The FDA has approved an oral treatment for advanced multiple myeloma called Zenbexus, which is the first drug cleared by U.S. regulators using a more sensitive measure of remission. This new drug belongs to a new class of blood cancer drugs called CELMoDs, which work by redirecting a cell's natural machinery to eliminate cancer-causing proteins. In other news, a U.S. appeals court ruled that a lower-court judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs. The court decided that UMB Bank was entitled to represent Celgene shareholders as a trustee despite an error in how it was appointed.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more",
        "url": "https://urgent.news/2026/08/13/stat-pharmalittle-were-reading-about-california-insulin-sales-a",
        "published": "2026-08-13T13:19:42.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}